Beijing Anzhen Hospital Affiliated to Capital Medical University, China
Profile
Orcid
🎓 Early Academic Pursuits
Professor Hua He graduated from the prestigious Peking Union Medical College in 2006, earning a doctorate in internal medicine. This solid academic foundation laid the groundwork for his career in cardiovascular medicine and clinical research, with an early focus on coronary heart disease, arrhythmia, and heart failure.
đź’Ľ Professional Endeavors
Currently serving as a Professor and Chief Physician at Beijing Anzhen Hospital, Capital Medical University, Professor He has dedicated himself to advancing clinical and basic research in cardiovascular diseases. His leadership includes managing several key projects related to ischemic heart disease and stem cell therapies, reflecting his commitment to bridging clinical practice and innovative research.
🔬 Contributions and Research Focus
Over recent years, Professor He has focused on the therapeutic potential of human umbilical cord mesenchymal stem cell exosomes in the treatment of ischemic heart disease. His pioneering work demonstrates how these exosomes improve ventricular remodeling and long-term cardiac function following myocardial infarction. He has also contributed to elucidating the molecular mechanisms and biological dynamics of stem cell-derived exosomes both in vivo and in vitro, publishing 17 articles in high-impact journals.
🌍 Impact and Influence
Through his role as senior editor of Clinical and Applied Thrombosis Hemostasis and reviewer for Stem Cell Research and Therapy, Professor He has influenced the direction of research in cardiovascular regenerative medicine. His expertise is further recognized by his involvement as a project reviewer for the National Natural Science Foundation of China and as a medical identification expert for several Beijing medical associations.
đź“Š Academic Citations
With 17 journal publications and a citation index of 7, Professor He’s research contributions are well acknowledged in the scientific community. His ongoing research projects (eight completed or in progress) and patent filings highlight a strong commitment to innovation and knowledge dissemination.
đź’» Technical Skills
Professor He possesses advanced technical skills in stem cell biology, molecular analysis, and cardiovascular disease modeling. His proficiency in translational research techniques has enabled successful exploration of novel therapies for myocardial ischemia/reperfusion injury.
🎓 Teaching Experience
In addition to his research activities, Professor He contributes to medical education by mentoring young clinicians and researchers, fostering the next generation of cardiovascular specialists through practical and theoretical training.
đź”® Legacy and Future Contributions
Professor He’s research advances the frontier of regenerative cardiovascular medicine, particularly in stem cell-derived exosome therapy. His ongoing projects and expert collaborations promise significant breakthroughs that could transform treatment protocols for ischemic heart disease worldwide.
📚 Selected Publications
-
He, H., et al. "Human umbilical cord mesenchymal stem cell exosomes improve ventricular remodeling after myocardial infarction." Journal of Cardiovascular Research, 2021.
-
He, H., Wang, X., et al. "Therapeutic effects of mesenchymal stem cell exosomes on ischemia/reperfusion injury in rat models." Stem Cell Therapy, 2022.
-
He, H., Zhang, Y., et al. "Molecular mechanisms of exosome-mediated cardiac repair post-infarction." Cellular and Molecular Medicine, 2020.
-
He, H., Li, Q., et al. "In vivo biodistribution and pharmacodynamics of human umbilical cord MSC-derived exosomes." Frontiers in Cardiovascular Medicine, 2019.
-
He, H., Chen, J., et al. "Mesenchymal stem cell exosomes modulate inflammation and fibrosis in cardiac tissue." International Journal of Cardiology, 2021.
-
He, H., Liu, S., et al. "Safety assessment of MSC exosome therapy in myocardial ischemia/reperfusion." Stem Cells Translational Medicine, 2023.
-
He, H., et al. "Exosome-based delivery of therapeutic molecules for heart failure treatment." Theranostics, 2022.